In October, 6 pharmaceutical companies were acquired and 8 pharmaceutical companies invested to establish new companies

In the pharmaceutical industry, the undercurrent of capital market is the norm The coming October is no exception According to incomplete statistics of public company announcements, six pharmaceutical companies will be acquired; eight pharmaceutical companies announced to invest in the establishment of new companies - the major integration of the whole industry is still ongoing ▍ acquisition of 6 pharmaceutical enterprises: on October 26, Kangmei Pharmaceutical Co., Ltd planned to acquire 90% equity of Inner Mongolia Dongbei six Pharmaceutical Group Co., Ltd (hereinafter referred to as "Dongbei six pharmaceutical"), a shareholder of Tongliao Dongfang Liqun Pharmaceutical Co., Ltd (hereinafter referred to as "Dongbei six pharmaceutical"), with a purchase price of 6.3 million yuan Dongfang Liqun is mainly engaged in the pharmaceutical distribution business and medical device sales business in Tongliao After this successful acquisition, it will help the company to rapidly develop its business in Tongliao, and promote the implementation of modern pharmaceutical logistics extension project and smart pharmacy project in Tongliao On October 26, Kyrgyz holdings issued the plan for purchase of major assets The announcement shows that Kyrgyz holdings intends to purchase 99.68% shares of Puhua pharmaceutical held by 46 natural persons such as Yang Hua with its own funds and bank's merger and acquisition loan funds After negotiation by all parties, the transaction price of 99.68% shares of Puhua pharmaceutical is tentatively determined as 618062200 yuan Puhua pharmaceutical is mainly engaged in the R & D, production and sales of Chinese patent medicine and chemical medicine, and its product treatment range includes Ophthalmology, dermatology, musculoskeletal system, etc Through this transaction, the listed company will improve its competitive advantages in the fields of proprietary Chinese medicine and chemical medicine, and expand its product categories to the fields of Ophthalmology, so as to further optimize the business product portfolio of the listed company On October 26, Zhongyuan Xiehe released a progress announcement on the transfer of 67% equity of Zhejiang Saishang Pharmaceutical Technology Co., Ltd On November 24, 2017, Zhongyuan Xiehe cell genetic engineering Co., Ltd signed the equity transfer agreement with Guangzhou DaSai Pharmaceutical Technology Co., Ltd and Jingjie on the transfer of 67% equity of Zhejiang Saishang Pharmaceutical Technology Co., Ltd., with the transfer amount of 60 million yuan On October 16, Qinghai pharmaceutical, a holding subsidiary of Shanghai Hyundai Pharmaceutical Co., Ltd., planned to transfer 45.16% of the shares of Qinghai pharmaceutical factory through the Shanghai United Property Rights Exchange, with the base price of no less than 423.6259 million yuan Qingyao group plans to transfer 45.16% of the equity of Qinghai pharmaceutical factory by listing, which is conducive to the company's business adjustment and the asset integration after the company's reorganization; on the other hand, the listing base price of this equity transfer is planned to be 423.6259 million yuan, which has a larger investment income than the consideration of 239.6743 million yuan obtained by the company in 2016 On October 10, Jilin Aodong Pharmaceutical Group Co., Ltd announced that the company purchased the registered capital of Jilin Aodong pharmacy chain Co., Ltd of 1.66 million yuan held by Jilin Zhengrong Pharmaceutical Co., Ltd with 330000 yuan After the acquisition, the company holds 1.66 million yuan of registered capital of Aodong pharmacy, accounting for 100.00% of the registered capital of Aodong pharmacy The company invests in Aodong pharmacy, aiming to further improve the layout of upstream and downstream pharmaceutical industry chain The capital increase funds are mainly used to build new pharmaceutical terminal retail stores, purchase single drugstores, pharmaceutical chain stores and pharmaceutical commercial distribution centers, accelerate the layout of pharmaceutical chain terminals, and strive to expand the business scale of Aodong pharmacy On October 8, Liuzhou Pharmaceutical Co., Ltd announced that it plans to acquire 60% equity of Guangxi Wantong Pharmaceutical Co., Ltd., with a transaction amount of 715.8 million yuan After the completion of this transaction, Wantong pharmaceutical will become a holding subsidiary of the company and be included in the scope of consolidated statements The announcement shows that Wantong pharmaceutical and the company's existing business have good complementarity and synergy On the one hand, its core products will use the company's hospital sales channels and retail outlets to achieve rapid market promotion and expand sales scale; on the other hand, the company's processing business of Chinese herbal pieces can provide high-quality APIs for Wantong pharmaceutical, which can be transformed into high-quality pharmaceutical products with high added value through the production and research and development capabilities of the target company, so as to realize complementary advantages and industrial interaction and improve Sustained profitability of both parties ▍ set up 8 pharmaceutical enterprises: strengthen the layout and expand the market of Kangmei Pharmaceutical Co., Ltd on October 26, Kangmei Pharmaceutical Co., Ltd announced that Kangmei health Cloud Service Co., Ltd., a subsidiary of Kangmei Pharmaceutical Co., Ltd., plans to invest 10 million yuan to set up a wholly-owned subsidiary in Zhengzhou City, Henan Province The newly established company will carry out intelligent medical care services in Henan Province, build a comprehensive platform for intelligent medical care services in Henan Province, which is conducive to the company's development of intelligent medical care market in Henan Province, and create a new mode of combined medical care services China Medical and Health Industry Co., Ltd On October 26, Beijing Meikang Yongzheng Pharmaceutical Co., Ltd (hereinafter referred to as "Meikang Yongzheng"), a subsidiary holding company of China's pharmaceutical and health industry, planned to establish Qinhuangdao General Medicine Co., Ltd with a registered capital of 40 million yuan jointly invested by Meikang Yongzheng and wankemei in order to further improve the layout of commercial terminal network and improve market competitiveness The data shows that the establishment of the new company can effectively strengthen the company's pharmaceutical business layout in Hebei Province, expand the operation network of Meikang Yongzheng, improve its sales scale and profitability, and maintain its market competitiveness On October 26, aer ophthalmology released an announcement that in order to seize the opportunity of rapid development of China's medical industry and carry out a faster and better industrial layout, Lhasa Liangshi, a wholly-owned subsidiary of aer ophthalmology hospital group Co., Ltd., plans to use its own funds 19, Ten million yuan was invested as a limited partner to establish Hunan Liangshi Changxing medical industry management partnership (hereinafter referred to as "Liangshi Changxing") Liangshi Changxing will mainly invest and manage ophthalmic hospital and ophthalmic outpatient department, reserve more high-quality M & A targets for the future development of the company, accelerate the expansion pace of ophthalmic hospital and ophthalmic outpatient department, and reserve more M & A targets for the future development of the company On October 22, Kangenbei announced that in order to accelerate the issuance and listing of shares in the overseas recognized qualified international securities market, the company plans to invest 96 yuan, After the establishment of Shanghai Kangjia Medical Technology Co., Ltd., a wholly-owned subsidiary invested by RMB 10 million in Shanghai Pudong New Area, Shanghai Kangjia intends to agree to establish a wholly-owned subsidiary in Hong Kong with an investment of no more than RMB 960 million in accordance with the equity structure adjustment and other related matters and progress needs involved in Jiahe bio's overseas listing According to the data, in order to seize the opportunity and accelerate the development, in accordance with the current domestic and foreign capital market policy support for emerging industries such as biomedicine, Jiahe biology intends to apply for initial public offering of shares and listing of Guanfu holdings in overseas recognized qualified international securities market through equity structure adjustment On October 21, Guanfu holding wholly invested in the establishment of "plastic rice technology (Chengdu) Co., Ltd." according to the needs of development planning and strategic layout The proposed registered capital is RMB 50 million, and plastic rice information plans to invest RMB 50 million with its own capital Plastic rice information invested in Chengdu plastic rice is intended to expand the market in Southwest China, deepen regional business and close to service customers, so as to improve the market coverage and new customers of plastic rice information On October 20, Chongqing Taiji Industry Co., Ltd and Mianyang Taiji pharmacy chain Co., Ltd invested 41.16 million yuan and 1.59 million yuan respectively, and jointly invested with the company holding Taiji Group Co., Ltd to establish Mianyang Taiji Real Estate Development Co., Ltd On October 20, Hainan Haiyao Investment Co., Ltd., a wholly-owned subsidiary of Hainan Haiyao Co., Ltd., increased its capital to Shanghai youcadi Biomedical Technology Co., Ltd (hereinafter referred to as "youcadi") with its own funds The current investment of Haiyao is 50 million yuan, of which 734384 yuan is included in the registered capital of ucadi Zhongsheng pharmaceutical Guangdong Zhongsheng Pharmaceutical Co., Ltd (hereinafter referred to as "the company") was established on October 18, 2018 The proposal on investment in the establishment of holding subsidiary and related party transaction was approved on February, and it was agreed that the company, Dongguan RuiChuang pharmaceutical research and development center and Ms Zhou Xueli, the related natural person, jointly invested to establish Guangdong Zhongsheng RuiChuang Biotechnology Co., Ltd with a registered capital of 100 million yuan In recent years, M & A has become one of the important ways for capital market to support the development of real economy Therefore, in the future, capital operation in line with industrial logic will still be a hot trend.